Literature DB >> 22929992

Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods.

Martijn J Schuemie1, Preciosa M Coloma, Huub Straatman, Ron M C Herings, Gianluca Trifirò, Justin Neil Matthews, David Prieto-Merino, Mariam Molokhia, Lars Pedersen, Rosa Gini, Francesco Innocenti, Giampiero Mazzaglia, Gino Picelli, Lorenza Scotti, Johan van der Lei, Miriam C J M Sturkenboom.   

Abstract

BACKGROUND: Drug safety monitoring relies primarily on spontaneous reporting, but electronic health care record databases offer a possible alternative for the detection of adverse drug reactions (ADRs).
OBJECTIVES: To evaluate the relative performance of different statistical methods for detecting drug-adverse event associations in electronic health care record data representing potential ADRs. RESEARCH
DESIGN: Data from 7 databases across 3 countries in Europe comprising over 20 million subjects were used to compute the relative risk estimates for drug-event pairs using 10 different methods, including those developed for spontaneous reporting systems, cohort methods such as the longitudinal gamma poisson shrinker, and case-based methods such as case-control. The newly developed method "longitudinal evaluation of observational profiles of adverse events related to drugs" (LEOPARD) was used to remove associations likely caused by protopathic bias. Data from the different databases were combined by pooling of data, and by meta-analysis for random effects. A reference standard of known ADRs and negative controls was created to evaluate the performance of the method. MEASURES: The area under the curve of the receiver operator characteristic curve was calculated for each method, both with and without LEOPARD filtering.
RESULTS: The highest area under the curve (0.83) was achieved by the combination of either longitudinal gamma poisson shrinker or case-control with LEOPARD filtering, but the performance between methods differed little. LEOPARD increased the overall performance, but flagged several known ADRs as caused by protopathic bias.
CONCLUSIONS: Combinations of methods demonstrate good performance in distinguishing known ADRs from negative controls, and we assume that these could also be used to detect new drug safety signals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22929992     DOI: 10.1097/MLR.0b013e31825f63bf

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  41 in total

1.  A Multiagent System for Integrated Detection of Pharmacovigilance Signals.

Authors:  Vassilis Koutkias; Marie-Christine Jaulent
Journal:  J Med Syst       Date:  2015-11-21       Impact factor: 4.460

2.  How Confident Are We about Observational Findings in Healthcare: A Benchmark Study.

Authors:  Martijn J Schuemie; M Soledad Cepeda; Marc A Suchard; Jianxiao Yang; Yuxi Tian; Alejandro Schuler; Patrick B Ryan; David Madigan; George Hripcsak
Journal:  Harv Data Sci Rev       Date:  2020-01-31

3.  Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.

Authors:  Martijn J Schuemie; Rosa Gini; Preciosa M Coloma; Huub Straatman; Ron M C Herings; Lars Pedersen; Francesco Innocenti; Giampiero Mazzaglia; Gino Picelli; Johan van der Lei; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

4.  Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system.

Authors:  Martijn J Schuemie; David Madigan; Patrick B Ryan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

5.  A comparison of the empirical performance of methods for a risk identification system.

Authors:  Patrick B Ryan; Paul E Stang; J Marc Overhage; Marc A Suchard; Abraham G Hartzema; William DuMouchel; Christian G Reich; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

6.  Evaluating performance of risk identification methods through a large-scale simulation of observational data.

Authors:  Patrick B Ryan; Martijn J Schuemie
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 7.  Clinical Data Reuse or Secondary Use: Current Status and Potential Future Progress.

Authors:  S M Meystre; C Lovis; T Bürkle; G Tognola; A Budrionis; C U Lehmann
Journal:  Yearb Med Inform       Date:  2017-09-11

8.  Accuracy of an automated knowledge base for identifying drug adverse reactions.

Authors:  E A Voss; R D Boyce; P B Ryan; J van der Lei; P R Rijnbeek; M J Schuemie
Journal:  J Biomed Inform       Date:  2016-12-16       Impact factor: 6.317

9.  A novel approach for propensity score matching and stratification for multiple treatments: Application to an electronic health record-derived study.

Authors:  Derek W Brown; Stacia M DeSantis; Thomas J Greene; Vahed Maroufy; Ashraf Yaseen; Hulin Wu; George Williams; Michael D Swartz
Journal:  Stat Med       Date:  2020-04-16       Impact factor: 2.373

10.  Handling Temporality of Clinical Events for Drug Safety Surveillance.

Authors:  Jing Zhao; Aron Henriksson; Maria Kvist; Lars Asker; Henrik Boström
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.